Discovery of 4-{4-[(3R)-3-Methylmorpholin-4-yl]-6-[1-(methylsulfonyl)cyclopropyl]pyrimidin-2-yl}-1H-indole (AZ20): a potent and selective inhibitor of ATR protein kinase with monotherapy in vivo antitumor activity.

ATR is an attractive new anticancer drug target whose inhibitors have potential as chemo- or radiation sensitizers or as monotherapy in tumors addicted to particular DNA-repair pathways. We describe the discovery and synthesis of a series of sulfonylmorpholinopyrimidines that show potent and selective ATR inhibition. Optimization from a high quality screening hit within tight SAR space led to compound 6 (AZ20) which inhibits ATR immunoprecipitated from HeLa nuclear extracts with an IC50 of 5 nM and ATR mediated phosphorylation of Chk1 in HT29 colorectal adenocarcinoma tumor cells with an IC50 of 50 nM. Compound 6 potently inhibits the growth of LoVo colorectal adenocarcinoma tumor cells in vitro and has high free exposure in mouse following moderate oral doses. At well tolerated doses 6 leads to significant growth inhibition of LoVo xenografts grown in nude mice. Compound 6 is a useful compound to explore ATR pharmacology in vivo.

[1]  M. Ikenaga,et al.  Excision-repair of 4-nitroquinolin-1-oxide damage responsible for killing, mutation, and cancer. , 1975, Basic life sciences.

[2]  Norio Miyaura,et al.  The Palladium-Catalyzed Cross-Coupling Reaction of Phenylboronic Acid with Haloarenes in the Presence of Bases , 1982 .

[3]  N. Miyaura,et al.  Palladium(0)-Catalyzed Cross-Coupling Reaction of Alkoxydiboron with Haloarenes: A Direct Procedure for Arylboronic Esters. , 1996 .

[4]  A. Carr,et al.  Protein kinase mutants of human ATR increase sensitivity to UV and ionizing radiation and abrogate cell cycle checkpoint control. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[5]  S. Schreiber,et al.  Overexpression of a kinase‐inactive ATR protein causes sensitivity to DNA‐damaging agents and defects in cell cycle checkpoints , 1998, The EMBO journal.

[6]  J. Sarkaria,et al.  Inhibition of ATM and ATR kinase activities by the radiosensitizing agent, caffeine. , 1999, Cancer research.

[7]  I. Kuntz,et al.  The maximal affinity of ligands. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[8]  Y Taya,et al.  A role for ATR in the DNA damage-induced phosphorylation of p53. , 1999, Genes & development.

[9]  J. Spence,et al.  Pharmacokinetic-Pharmacodynamic Consequences and Clinical Relevance of Cytochrome P450 3A4 Inhibition , 2000, Clinical pharmacokinetics.

[10]  Roger L. Williams,et al.  Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine. , 2000, Molecular cell.

[11]  Jun Qin,et al.  ATR and ATRIP: Partners in Checkpoint Signaling , 2001, Science.

[12]  T. Weinert,et al.  Toward maintaining the genome: DNA damage and replication checkpoints. , 2002, Annual review of genetics.

[13]  F. Allen.  The Cambridge Structural Database: a quarter of a million crystal structures and rising. , 2002, Acta crystallographica. Section B, Structural science.

[14]  T. DeWeese,et al.  Enhanced radiation and chemotherapy-mediated cell killing of human cancer cells by small inhibitory RNA silencing of DNA repair factors. , 2003, Cancer research.

[15]  N. Curtin,et al.  Identification and Characterization of a Novel and Specific Inhibitor of the Ataxia-Telangiectasia Mutated Kinase ATM , 2004, Cancer Research.

[16]  J. Gautier,et al.  Regulation of DNA replication by ATR: signaling in response to DNA intermediates. , 2004, DNA repair.

[17]  A. Hopkins,et al.  Ligand efficiency: a useful metric for lead selection. , 2004, Drug discovery today.

[18]  W. Kaelin.  The Concept of Synthetic Lethality in the Context of Anticancer Therapy , 2005, Nature Reviews Cancer.

[19]  J. Kenny,et al.  AUTOMATED ASSESSMENT OF TIME-DEPENDENT INHIBITION OF HUMAN CYTOCHROME P450 ENZYMES USING LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY ANALYSIS , 2005, Drug Metabolism and Disposition.

[20]  M. Garrett,et al.  Targeting the cell division cycle in cancer: CDK and cell cycle checkpoint kinase inhibitors. , 2005, Current opinion in pharmacology.

[21]  B. Small,et al.  Optimisation and validation of a medium-throughput electrophysiology-based hERG assay using IonWorks HT. , 2006, Journal of pharmacological and toxicological methods.

[22]  F. Bunz,et al.  Loss of ataxia telangiectasia mutated– and Rad3-related function potentiates the effects of chemotherapeutic drugs on cancer cell survival , 2007, Molecular Cancer Therapeutics.

[23]  Brett A Tounge,et al.  The role of molecular size in ligand efficiency. , 2007, Bioorganic & medicinal chemistry letters.

[24]  A. Kalgutkar,et al.  Mechanism-based inactivation of cytochrome P450 enzymes: chemical mechanisms, structure-activity relationships and relationship to clinical drug-drug interactions and idiosyncratic adverse drug reactions. , 2007, Current drug metabolism.

[25]  Daniela Gabriel,et al.  Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity , 2008, Molecular Cancer Therapeutics.

[26]  K. Cimprich,et al.  ATR: an essential regulator of genome integrity , 2008, Nature Reviews Molecular Cell Biology.

[27]  Mindy I. Davis,et al.  A quantitative analysis of kinase inhibitor selectivity , 2008, Nature Biotechnology.

[28]  Gary Box,et al.  The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer . , 2008, Journal of medicinal chemistry.

[29]  N. Brooijmans,et al.  Morpholine derivatives greatly enhance the selectivity of mammalian target of rapamycin (mTOR) inhibitors. , 2009, Journal of medicinal chemistry.

[30]  Sean Ekins,et al.  Integrated in silico-in vitro strategy for addressing cytochrome P450 3A4 time-dependent inhibition. , 2010, Chemical research in toxicology.

[31]  B. Faller,et al.  CYP3A Time-Dependent Inhibition Risk Assessment Validated with 400 Reference Drugs , 2011, Drug Metabolism and Disposition.

[32]  C. Ly,et al.  Potent, selective, and orally bioavailable inhibitors of mammalian target of rapamycin (mTOR) kinase based on a quaternary substituted dihydrofuropyrimidine. , 2011, Journal of medicinal chemistry.

[33]  P. Reaper,et al.  Discovery of potent and selective inhibitors of ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase as potential anticancer agents. , 2011, Journal of medicinal chemistry.

[34]  Oscar Fernandez-Capetillo,et al.  Targeting ATR and Chk1 kinases for cancer treatment: A new model for new (and old) drugs , 2011, Molecular oncology.

[35]  James R Bischoff,et al.  A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations , 2011, Nature Structural &Molecular Biology.

[36]  Lisa L. Smith,et al.  Abstract 1823: AZ20, a novel potent and selective inhibitor of ATR kinase with in vivo antitumour activity , 2012 .

[37]  S. Burma,et al.  The dual PI3K/mTOR inhibitor NVP-BEZ235 is a potent inhibitor of ATM- and DNA-PKCs-mediated DNA damage responses. , 2012, Neoplasia.

[38]  G. Lamont,et al.  Sulfonyl-morpholino-pyrimidines: SAR and development of a novel class of selective mTOR kinase inhibitor. , 2012, Bioorganic & medicinal chemistry letters.

[39]  R. Muschel,et al.  The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy , 2012, Cancer biology & therapy.

[40]  R. Griffin,et al.  Modulation of DNA repair by pharmacological inhibitors of the PIKK protein kinase family. , 2012, Bioorganic & medicinal chemistry letters.

[41]  Akos Tarcsay,et al.  Impact of lipophilic efficiency on compound quality. , 2012, Journal of medicinal chemistry.

[42]  S. Burma,et al.  The Dual PI 3 K / mTOR Inhibitor NVP-BEZ 235 Is a Potent Inhibitor of ATM-and DNA-PKCs-Mediated DNA Damage Responses 1 , 2 , 2014 .